Our findings suggest that designing inhibitors targeting the ALG3-FOXD1-BNIP3 axis or mitophagy represents a promising therapeutic approach to improve the efficacy of gemcitabine treatment for NPC. Here, FOXD1 is linked to nasopharyngeal carcinoma.